Abstract β2-agonists provide necessary bronchodilatory action, are recommended by
existing clinical practice guidelines and are widely prescribed for patients with these …

Objective: This study aimed to quantitatively compare the efficacy and safety of long-acting
β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations …

Background and objective While several studies have found that prescribing practices do
not conform to chronic obstructive pulmonary disease (COPD) treatment guidelines, none …

Educational aims To discuss fundamental questions relating to the use of bronchodilators
that can lead to an optimisation of their utilisation. To describe new bronchodilators that …

Determining which patients with COPD may benefit from a nebulized long-acting beta2-
agonist (LABA) is a challenge in current practice. In the absence of strong clinical guidelines …

Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-
acting β2-agonists (LABAs) in combination is currently the mainstay of treatment for chronic …

Abstract The Global Initiative for Chronic Obstructive Lung Disease (GOLD)
recommendations for the initial bronchodilator to use in newly diagnosed chronic obstructive …

Some trials have been conducted to compare long‐acting muscarinic antagonist (LAMA)+
long‐acting beta agonist (LABA) versus LABA+ inhaled corticosteroids (ICS) for chronic …

Highlights•Selective BBs in COPD were not associated with relevant worsening of
pulmonary function.•Selective BBs could be used in COPD with CVD comorbidities.•In …

OBJECTIVE: The effect of short-acting inhaled β2-agonists on mortality from chronic
obstructive pulmonary disease (COPD) is controversial. Different observational designs …